The adjunctive use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) as an addition to insulin is increasingly viewed as a method for addressing the rising prevalence of obesity in type 1 diabetes (T1D). Current GLP-1 RA drugs, such as semaglutide and the dual glucagon-insulinotropic peptide (GIP)/GLP-1 tirzepatide...
256 W Beech St P.O. Box 32 Harrison, Michigan, USA 48625
(989) 424-9929
austin@clippershipsandcaravans.com
Copyright © 2023 roenews2. All Rights Reserved
